[Table/Fig-8]:
Antibiotic susceptibility pattern.
| Antibioticdiscs |
Klebsiella pneumonia (n = 71) |
Coag + Staph (n = 43) |
Pseudomonas aeruginosa (n = 23) | Coag – staph (n = 18) |
Esch. Coli (n = 11) |
Proteus mirabilis (n = 5) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | R | S | R | S | R | S | R | S | R | S | R | |
| Ampicillin | NA | - | 6 | 37 | NA | - | 3 | 15 | NA | - | NA | - |
| Ampicillin + Sulbactum | 42 | 29 | 18 | 25 | 4 | 19 | 7 | 11 | 7 | 4 | 4 | 1 |
| Augmentin | 18 | 53 | 17 | 26 | 3 | 20 | 6 | 12 | 5 | 6 | 4 | 1 |
| Amikacin | 59 | 12 | 38 | 5 | 9 | 14 | 13 | 5 | 8 | 3 | 5 | 0 |
| Cephoxitin | NA | - | 25 | 18 | NA | - | 7 | 11 | NA | - | NA | - |
| Cefotaxime | 37 | 34 | NA | - | 8 | 15 | NA | - | 4 | 7 | 4 | 1 |
| Cefotaxime + Clavulanic acid * | 49 | 22 | NA | - | 12 | 11 | NA | - | 8 | 3 | 4 | 1 |
| Ceftazidime | 38 | 31 | NA | - | 9 | 14 | NA | - | 5 | 6 | 3 | 2 |
| Ceftazidime + clavulanic acid * | 51 | 20 | NA | - | 14 | 9 | NA | - | 9 | 2 | 4 | 1 |
| Ceftriaxone | 36 | 35 | 21 | 22 | 9 | 14 | 7 | 11 | 4 | 7 | 2 | 3 |
| Ciprofloxacin | 16 | 55 | 12 | 31 | 3 | 20 | 3 | 15 | 3 | 8 | 2 | 3 |
| Chloramphenicol | 18 | 53 | 19 | 24 | 2 | 21 | 5 | 13 | 2 | 9 | 1 | 4 |
| Erythromycin | 23 | 48 | 22 | 21 | 4 | 19 | 4 | 14 | 1 | 10 | 2 | 3 |
| Gentamycin | 29 | 42 | 17 | 26 | 7 | 16 | 7 | 11 | 3 | 8 | 3 | 2 |
| Imipenam | 63 | 8 | NA | - | 2 | 21 | NA | - | 2 | 9 | 5 | 0 |
| Netilmycin | 52 | 19 | NA | - | 8 | 15 | NA | - | 7 | 4 | 5 | 0 |
| Ofloxacin | 13 | 58 | 25 | 18 | 3 | 20 | 6 | 12 | 2 | 9 | 2 | 3 |
| Tetracycline | 46 | 25 | 27 | 16 | 6 | 17 | 11 | 7 | 5 | 6 | 3 | 2 |
| Vancomycin | NA | - | 43 | 0 | NA | - | 18 | 0 | NA | - | NA | - |
Note: * Sensitivity of cefotaxime + clavulanic acid and ceftazidime + clavulanic acid considered only when there is > 5 mm increase in the zone diameter of these drugs as compared to cefotaxime and ceftazime disc alone (ESBL production indicator)